Literature DB >> 9127830

Depressive retardation and treatment with fluoxetine: assessment of the motor component.

B Sabbe1, J van Hoof, W Hulstijn, F Zitman.   

Abstract

Changes in motor slowing between the start and end of treatment were studied in 22 inpatients with a Major Depressive Episode and 22 normal, healthy control persons. The degree and pattern of motor slowing were measured and analysed using computer-aided simple drawing tasks that did not require any higher order cognitive processing. The patients were treated with fluoxetine 20 mg/day for 6 weeks. Tests took place after 1 week (T0) and 6 weeks (T1). At T0 patients showed marked slowing, apparent in longer movement times and lower velocities than their controls. The differences between groups increased as the size of the movement increased or the accuracy demands increased. In all the trials, patients showed clear initiation difficulties. At T1 the motor slowing of the depressed patients had improved, but not disappeared. Significant differences remained between the two groups.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9127830     DOI: 10.1016/s0165-0327(96)01409-7

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  4 in total

Review 1.  Psychomotor slowing in schizophrenia.

Authors:  Manuel Morrens; Wouter Hulstijn; Bernard Sabbe
Journal:  Schizophr Bull       Date:  2006-11-08       Impact factor: 9.306

Review 2.  Psychomotor retardation in depression: biological underpinnings, measurement, and treatment.

Authors:  Jeylan S Buyukdura; Shawn M McClintock; Paul E Croarkin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-10-31       Impact factor: 5.067

3.  Differential effects of reboxetine and citalopram on hand-motor function in patients suffering from major depression.

Authors:  Ulrich Hegerl; Roland Mergl; Verena Henkel; Oliver Pogarell; Florian Müller-Siecheneder; Thomas Frodl; Georg Juckel
Journal:  Psychopharmacology (Berl)       Date:  2004-08-13       Impact factor: 4.530

4.  Mapping the physiological and molecular markers of stress and SSRI antidepressant treatment in S100a10 corticostriatal neurons.

Authors:  Derya Sargin; Revathy U Chottekalapanda; Kristina E Perit; Victoria Yao; Duong Chu; Daniel W Sparks; Salina Kalik; Saige K Power; Olga G Troyanskaya; Eric F Schmidt; Paul Greengard; Evelyn K Lambe
Journal:  Mol Psychiatry       Date:  2019-08-20       Impact factor: 15.992

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.